ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026
Increased Frequency of the Chemokine Receptor CCR2 on Circulating CD19+CD5+ Lymphocytes in Therapy-Naïve CLL Patients With the Detectable EBV DNA and High-Avidity Antibodies Against the EBV Capsid Antigen.
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Increased Frequency of the Chemokine Receptor CCR2 on Circulating CD19+CD5+ Lymphocytes in Therapy-Naïve CLL Patients With the Detectable EBV DNA and High-Avidity Antibodies Against the EBV Capsid Antigen.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High EBV load in peripheral blood (PB) of untreated patients with chronic lymphocytic leukemia (CLL) has been associated with shorter overall survival. We demonstrated previously that EBV infection of B cells upregulates CCR1 and CCR2. For 54 therapy-naïve CLL patients of the present study, we analyzed expression of CCR1, CCR2, and CD38 on circulating CD19+CD5+ lymphocytes, determined the EBV load (EBV DNA copy number) and the EBV transcripts (BZLF1, LMP1, LMP2A, and EBNA2) in PB mononuclear cells (PBMCs), and measured levels and avidity of IgG antibodies against the EBV capsid antigen (anti-EBV-CA-IgG). The BZLF1 transcript was determined in one patient; both LMP1 and EBNA2 transcripts were detected in two patients only, and, in these patients, the frequency of CD19+CD5+ lymphocytes that presented CCR1 or CCR2 was elevated by 2.5-, 4.3-, and 2.9-fold and by 2.1-, 1.2-, and 2.9-fold, respectively, relative to the median values in the EBV-positive group (> 5 EBV DNA copies in 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.